TREATMENT PATTERNS, HEALTHCARE RESOURCE UTILIZATION, AND COSTS OF CARE AMONG PATIENTS WITH NEWLY DIAGNOSED SYSTOLIC AND DIASTOLIC HEART FAILURE IN A US REAL-WORLD SETTING

Author(s)

Nguyen C1, Zhang X1, Evers T2, Willey VJ1, Tan H1, Power TP3
1HealthCore, Inc., Wilmington, DE, USA, 2Bayer AG, Wuppertal, Germany, 3AIM Specialty Health, Chicago, IL, USA

Presentation Documents

OBJECTIVES : The study aimed to explore differential burden of illness between systolic (SHF) and diastolic heart failure (DHF) and further examined HF-related medication effects among SHF patients.

METHODS : This was an observational retrospective cohort study using administrative claims data from a large U.S. national health insurer integrated with the Social Security Death Index. Newly-diagnosed HF patients were identified between 01/01/2010 through 06/30/2016 and grouped according to SHF or DHF diagnosis. Patients were followed for up to 4 years post-diagnosis. Treatment patterns, healthcare resource utilization (HCRU), costs and mortality were compared between SHF and DHF patients and analyzed using multivariable models.

RESULTS : The study included 46,885 SHF and 21,854 DHF patients. SHF had less HCRU vs DHF during the first year after HF diagnosis: hospital admissions (70.2% vs 82.4%, p<0.001) and ED visits (30.5% vs 39.1%, p<0.001); but higher annual all-cause ($64,154 vs $59,652, p<0.001) and HF-related costs ($39,957 vs $32,617, p<0.001). After adjusting for baseline characteristics, DHF patients had greater hospitalization risk (OR 1.62; 95% CI 1.55-1.69), however comparable adjusted costs (exponentiated estimate 1.01; 95% CI 0.99-1.02). The adjusted all-cause mortality during entire follow-up period was slightly lower in DHF than SHF (HR 0.96; 95% CI 0.93-0.99).

Multivariable analysis among SHF patients showed the benefits of receiving 1, 2, or ≥3 HF-related medication classes during the year preceding HF diagnosis in lowering hospitalization (OR 0.64, 0.55, 0.55), costs (exponentiated estimate 0.88, 0.85, 0.83) and mortality risks (HR= 0.91, 0.89, 0.89), respectively (all p-values<0.001). Of note, 21.9% SHF patients were taking no HF medication in the year following diagnosis.

CONCLUSIONS : This real-world analysis confirmed a high disease burden across all HF and documented the association of improved outcomes with recommended HF therapies in SHF. The high rate of untreated patients underscored a gap in care and provided an opportunity for intervention.

Conference/Value in Health Info

2019-05, ISPOR 2019, New Orleans, LA, USA

Value in Health, Volume 22, Issue S1 (2019 May)

Code

PCV55

Topic

Economic Evaluation

Topic Subcategory

Cost/Cost of Illness/Resource Use Studies

Disease

Cardiovascular Disorders

Explore Related HEOR by Topic


Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×